ALXN1820

Unknown / undisclosed

Phase 2Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Development in Sickle Cell Disease stopped for reasons the sponsor has not stated. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
ANCA-Associated Vasculitis
NCT07160608 · Alexion Pharmaceuticals, Inc.
2025-11-26 – 2028-02-14 · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
What this study did
Other / comorbidity
NCT05565092 · Alexion Pharmaceuticals, Inc.
2023-02-22 – 2024-01-09 · Sickle Cell Disease (SCD)
What this study did
Phase 1 (1)
Other / comorbidity
NCT04631562 · Alexion Pharmaceuticals, Inc.
2021-01-13 – 2022-09-01 · Healthy
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow ALXN1820 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Phase 2ANCA-Associated VasculitisActive not recruiting
Est. primary completion 2027-10-11 · NCT07160608 · CT.gov ↗
What to watch

See the full readout calendar ↗